Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot studyAndrew McGarry, Ruin Moaddel, Basant Pradhan et al.|Scientific Reports|2020Cited by 38
Galantamine-Memantine Combination in the Treatment of Parkinson’s Disease DementiaEmma D. Frost, Maju Mathew Koola, Vishnu Byroju et al.|Brain Sciences|2024Cited by 11
An exploratory metabolomic comparison of participants with fast or absent functional progression from 2CARE, a randomized, double-blind clinical trial in Huntington’s diseaseAndrew McGarry, Ruin Moaddel, Josephine M. Egan et al.|Scientific Reports|2024Cited by 9